AutoimmuneICD-10: M34.9Affects approximately 75,000-100,000 people in the United States

Scleroderma

Scleroderma is a group of rare autoimmune diseases that cause hardening and tightening of the skin and connective tissues due to overproduction of collagen. In systemic scleroderma, the disease can also affect blood vessels and internal organs including the lungs, heart, kidneys, and digestive tract. The condition ranges from localized forms affecting only the skin to diffuse systemic sclerosis, which can be life-threatening.

Last updated November 10, 2026

Understanding Scleroderma

Scleroderma means hard skin, and the term covers two different problems. Localized scleroderma (morphea) causes patches or bands of thickened skin and never spreads to internal organs. Systemic sclerosis, the form most people mean, is an autoimmune disease in which small blood vessels are damaged and the body lays down excess collagen in the skin and in the lungs, gut, heart and kidneys. It is rare: about 240 people per million in the United States, roughly 75,000 to 100,000 people, with around 20 new cases per million each year. Women outnumber men four to one, onset is usually between 30 and 50, and Black Americans tend to develop it younger and in the more aggressive diffuse form. About two thirds of people have limited cutaneous disease, with skin thickening confined to the hands, forearms, feet and face (formerly called CREST), and one third have diffuse disease, where thickening spreads above the elbows and knees and onto the trunk, usually within the first 1 to 3 years.

The earliest event is injury to the lining of small arteries, which is why Raynaud's phenomenon (fingers blanching white, then blue, in the cold) precedes other symptoms by years in limited disease and is present in 95 percent of people overall. Immune cells and autoantibodies then activate fibroblasts, which overproduce collagen, stiffening skin and sometimes lung and heart tissue. The autoantibody found predicts the pattern: anticentromere antibodies go with limited disease and a later risk of pulmonary hypertension; anti-Scl-70 (topoisomerase I) with diffuse disease and lung fibrosis; anti-RNA polymerase III with rapidly thickening skin, a roughly 25 percent risk of renal crisis and a higher chance of a hidden cancer around the time of onset. Skin thickening in diffuse disease usually peaks within 1 to 3 years and then softens on its own. The organs decide the outcome: interstitial lung disease affects about half of people and pulmonary arterial hypertension about 10 percent, and together they cause roughly 60 percent of disease-related deaths, while renal crisis now affects about 5 percent.

There is no single drug for systemic sclerosis; treatment targets each organ, following the EULAR recommendations and the 2023 American College of Rheumatology guideline for autoimmune lung disease. For lung fibrosis, mycophenolate is first line: in Scleroderma Lung Study II (142 people), 2 years of mycophenolate preserved lung function as well as a year of cyclophosphamide with fewer side effects. Nintedanib slowed the yearly loss of lung volume by 44 percent in the 576-person SENSCIS trial, tocilizumab stabilized lung function in the focuSSced trial and is FDA approved for this use, and rituximab is an option for skin and lung. For selected people with rapidly progressive diffuse disease, autologous stem cell transplantation produced event-free survival of 79 percent at 4.5 years versus 50 percent with cyclophosphamide in the SCOT trial. Raynaud's is treated with nifedipine or amlodipine, then sildenafil; iloprost infusions heal digital ulcers and bosentan prevents new ones. Renal crisis is a same-day emergency treated with captopril, which turned a nearly always fatal complication into one with about 70 percent one-year survival.

No supplement softens scleroderma skin or reverses fibrosis, and claims to the contrary deserve suspicion. Older candidates have been tested and failed: high-dose D-penicillamine was no better than a token dose in a 134-person trial, and potassium aminobenzoate, DMSO and vitamin E have no controlled evidence. The honest uses of natural products are narrow. Ginkgo biloba reduced Raynaud's attacks by 56 percent versus 27 percent for placebo in a small trial, though a later head-to-head found nifedipine clearly better. Fish oil improved cold tolerance in primary Raynaud's but not in the secondary form that goes with scleroderma. Probiotics have been tried for the bloating and reflux of scleroderma gut disease with mixed results in two small randomized trials. Vitamin D deficiency affects most people with the disease and is worth correcting for bone health, since osteoporosis is common. Be careful with laxative or bile-stimulating herbs if your gut is slow, and avoid products sold as immune stimulants (echinacea, high-dose astragalus) while on mycophenolate or other immunosuppressants: they work against the treatment and have no evidence of their own.

The most common mistake is to focus on the visible problems (cold fingers, tight skin, heartburn) and skip the screening for the silent ones. Lung fibrosis and pulmonary hypertension cause few symptoms until they are advanced, which is why guidelines call for pulmonary function tests every 4 to 6 months in the first 3 to 5 years of diffuse disease, a high-resolution CT of the chest at diagnosis, and an echocardiogram every year for life. Ask for a BNP, hemoglobin and ferritin too, since slow bleeding from stomach blood vessels (watermelon stomach) is a common cause of unexplained anemia. The second mistake is taking prednisone at more than 15 mg a day for joint pain, the strongest modifiable risk factor for renal crisis in early diffuse disease. Check your blood pressure at home at least weekly during the first 4 years, daily if you have anti-RNA polymerase III antibodies or have just started a steroid: a reading above 150/85, or a rise of 20 points over your usual, with headache, blurred vision or breathlessness, needs same-day medical review.

At a Glance

Common symptoms
Thickening and hardening of the skin, especially on the fingers and face, Raynaud's phenomenon (fingers turning white or blue in response to cold or stress), Swollen, stiff, or painful joints
Main treatments
Immunosuppressants (mycophenolate, methotrexate, cyclophosphamide) to slow disease progression, Calcium channel blockers (nifedipine) or PDE5 inhibitors for Raynaud's phenomenon, Proton pump inhibitors for gastrointestinal symptoms
Category
Autoimmune · Affects approximately 75,000-100,000 people in the United States
See a doctor if
You notice unexplained skin thickening or tightening

Symptoms

Thickening and hardening of the skin, especially on the fingers and face
Raynaud's phenomenon (fingers turning white or blue in response to cold or stress)
Swollen, stiff, or painful joints
Difficulty swallowing (dysphagia) and acid reflux
Shortness of breath and dry cough from lung involvement
Skin ulcers on the fingertips
Fatigue and generalized weakness
Calcium deposits under the skin (calcinosis)

Causes

  • Overproduction of collagen by the immune system attacking connective tissue
  • Abnormal immune system activation and autoantibody production
  • Vascular damage leading to tissue fibrosis
  • Genetic predisposition combined with environmental triggers
  • Possible environmental exposures to silica dust, organic solvents, or certain drugs

Risk Factors

  • Female sex (women are affected 3-4 times more often than men)
  • Age between 30 and 50 years at onset
  • Family history of autoimmune diseases
  • Exposure to silica dust or polyvinyl chloride
  • African American or Native American descent (higher risk for severe forms)

Diagnosis

  • Physical examination of skin changes and Raynaud's phenomenon
  • Blood tests for autoantibodies (anti-centromere, anti-Scl-70, anti-RNA polymerase III)
  • Pulmonary function tests and high-resolution CT scan for lung involvement
  • Echocardiogram to assess heart and pulmonary artery pressure
  • Skin biopsy to confirm collagen overproduction
  • Nail fold capillaroscopy to examine small blood vessels

Treatment

  • Immunosuppressants (mycophenolate, methotrexate, cyclophosphamide) to slow disease progression
  • Calcium channel blockers (nifedipine) or PDE5 inhibitors for Raynaud's phenomenon
  • Proton pump inhibitors for gastrointestinal symptoms
  • ACE inhibitors for scleroderma renal crisis
  • Physical and occupational therapy to maintain joint flexibility
  • Antifibrotic drugs (nintedanib) for progressive lung fibrosis

Natural remedies for scleroderma: what the evidence says

Ranked by the strength of human evidence for scleroderma specifically. These sit alongside medical care, not in place of it.

  1. Ginkgo Biloba

    Preliminary evidence

    In a 10-week placebo-controlled trial of 22 people with primary Raynaud's, standardized ginkgo extract reduced the number of weekly attacks by 56 percent compared with 27 percent on placebo, without changing attack severity. A later 8-week trial in 41 people found nifedipine cut attacks by 50 percent against 31 percent for ginkgo. There is no trial specifically in scleroderma-related Raynaud's, where the vessels are structurally narrowed, so expect less.

    Studied dose
    120 mg of standardized extract (24 percent flavone glycosides) three times daily, as studied.
    Cautions
    Increases bleeding risk with warfarin, apixaban, aspirin, clopidogrel and NSAIDs, which matters if you have watermelon stomach; stop 2 weeks before procedures. May add to the blood-pressure drop from sildenafil. Not a substitute for calcium channel blockers.
  2. Omega-3

    Preliminary evidence

    In a 17-week placebo-controlled trial of 32 people with Raynaud's, high-dose fish oil (about 4 g EPA and 2.6 g DHA daily) lengthened the time to vasospasm in cold-water testing and improved symptoms in those with primary Raynaud's, but produced no measurable benefit in people with scleroderma. Nothing shows it changes skin, lung or gut disease in systemic sclerosis, though 1 g daily has general cardiovascular safety data.

    Studied dose
    1 to 2 g combined EPA and DHA daily with food if used; higher doses were studied in scleroderma without benefit.
    Cautions
    Adds to bleeding risk with anticoagulants and antiplatelets; doses of 4 g raise atrial fibrillation risk. Stop before surgery or iloprost infusions if advised.
  3. Gut symptoms affect 90 percent of people with systemic sclerosis. In a 2019 placebo-controlled trial of 73 people, 8 weeks of a multi-strain probiotic did not improve overall gut symptom scores, though it reduced anxiety. A separate 60-day trial of 40 people reported better reflux scores with a Lactobacillus and Bifidobacterium blend but no change in bloating, constipation or diarrhea. Probiotics do not treat small intestinal bacterial overgrowth, which needs antibiotics.

    Studied dose
    A multi-strain Lactobacillus and Bifidobacterium product of 10 to 50 billion CFU daily for an 8-week trial, stopped if there is no benefit.
    Cautions
    Ask your rheumatologist first if you have a central venous line or are on high-dose immunosuppression, because of rare bloodstream infections. Can worsen bloating in people with bacterial overgrowth.
  4. Vitamin D

    Preliminary evidence

    Low 25-hydroxyvitamin D is found in roughly 80 percent of people with systemic sclerosis, partly because thickened skin makes less of it, and low levels track with worse disease in observational studies. No randomized trial shows supplementation changes skin or lung outcomes. Its value is in bone: osteoporosis affects about a quarter of people with the disease, driven by malabsorption, inflammation and steroid exposure, and vitamin D with calcium is standard prevention.

    Studied dose
    1,000 to 2,000 IU vitamin D3 daily, adjusted to a 25-hydroxyvitamin D level of at least 30 ng/mL; take with food.
    Cautions
    High doses raise calcium; test rather than guess. Take several hours apart from bile acid sequestrants and orlistat, which block its absorption.

What matters day to day

  • Keep your core warm, not just your hands: wear layers, heated gloves and a hat, warm the car first and use insulated cups, because Raynaud's attacks are triggered by whole-body cooling and each attack starves fingertip tissue that is already short of blood.
  • Stop smoking and avoid nicotine, decongestants such as pseudoephedrine, triptans and stimulant medicines where possible: all constrict small vessels, and smokers with scleroderma have about three to four times more digital ulcers and amputations.
  • Check your blood pressure at home weekly for the first 4 years of diffuse disease and write it down: a jump of 20 mmHg or a reading over 150/85 may be renal crisis, which is treatable only if caught within hours to days.
  • Manage reflux mechanically as well as with medication: eat small meals, nothing in the 3 hours before bed, and raise the head of the bed 6 to 8 inches on blocks, because the weakened esophagus cannot clear acid and chronic reflux is linked to worse lung fibrosis.
  • Stretch hands and face daily and keep exercising: hand exercises plus paraffin wax improved grip and finger movement in trials, mouth-opening exercises preserve access for dental care, and supervised aerobic and resistance exercise improved fitness and fatigue without flaring the disease.
  • Moisturize twice a day with a thick emollient, protect fingertips from knocks, and see your clinician within days for any new fingertip sore: early treatment of digital ulcers prevents the infection and bone involvement that otherwise lead to amputation in a minority.

Prevention

  • No known prevention, but early diagnosis improves outcomes
  • Avoid cold exposure and keep extremities warm to reduce Raynaud's episodes
  • Quit smoking to protect blood vessel health
  • Minimize exposure to silica dust and industrial chemicals
  • Regular monitoring of blood pressure and kidney function

When to See a Doctor

  • You notice unexplained skin thickening or tightening
  • Your fingers change color dramatically in response to cold or stress
  • You develop persistent difficulty swallowing, shortness of breath, or joint stiffness

Frequently Asked Questions

References

  1. Denton CP, Khanna D. Systemic sclerosis. Lancet (2017)
  2. Kowal-Bielecka O, Fransen J, Avouac J, et al.. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases (2017)
  3. Johnson SR, Bernstein EJ, Bolster MB, et al.. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis and Rheumatology (2024)
  4. Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine (2016)
  5. Distler O, Highland KB, Gahlemann M, et al.. Nintedanib for systemic sclerosis-associated interstitial lung disease. New England Journal of Medicine (2019)
  6. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al.. Myeloablative autologous stem-cell transplantation for severe scleroderma. New England Journal of Medicine (2018)
  7. Tyndall AJ, Bannert B, Vonk M, et al.. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases (2010)
  8. Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vascular Medicine (2002)
  9. Marighela TF, Arismendi MI, Marvulle V, et al.. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial. Rheumatology (Oxford) (2019)
  10. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Scleroderma (2024)View source

Related Conditions

Have questions about Scleroderma?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.